CN111588657A - 一种玻色因及蓝铜肽双效组合精华液及其制备方法 - Google Patents
一种玻色因及蓝铜肽双效组合精华液及其制备方法 Download PDFInfo
- Publication number
- CN111588657A CN111588657A CN202010520199.6A CN202010520199A CN111588657A CN 111588657 A CN111588657 A CN 111588657A CN 202010520199 A CN202010520199 A CN 202010520199A CN 111588657 A CN111588657 A CN 111588657A
- Authority
- CN
- China
- Prior art keywords
- phase
- parts
- stirring
- cooling
- phenoxyethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 title description 9
- 241000530268 Lycaena heteronea Species 0.000 title description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 48
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 238000003756 stirring Methods 0.000 claims abstract description 28
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 22
- 238000001816 cooling Methods 0.000 claims abstract description 17
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000004310 lactic acid Substances 0.000 claims abstract description 16
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 16
- 239000006166 lysate Substances 0.000 claims abstract description 16
- 229960005323 phenoxyethanol Drugs 0.000 claims abstract description 16
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 16
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 16
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 16
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 12
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 150000004676 glycans Chemical class 0.000 claims abstract description 7
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 7
- 239000005017 polysaccharide Substances 0.000 claims abstract description 7
- 229940015975 1,2-hexanediol Drugs 0.000 claims abstract description 6
- DDADCBXAKYGDEH-UHFFFAOYSA-N 2-(3-hydroxypropyl)oxane-2,3,4-triol Chemical compound OCCCC1(O)OCCC(O)C1O DDADCBXAKYGDEH-UHFFFAOYSA-N 0.000 claims abstract description 6
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000007599 discharging Methods 0.000 claims abstract description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 238000000855 fermentation Methods 0.000 claims description 19
- 230000004151 fermentation Effects 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 10
- 239000005740 Boscalid Substances 0.000 claims description 9
- WYEMLYFITZORAB-UHFFFAOYSA-N boscalid Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1NC(=O)C1=CC=CN=C1Cl WYEMLYFITZORAB-UHFFFAOYSA-N 0.000 claims description 9
- 229940118790 boscalid Drugs 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 8
- -1 polydimethylsiloxane Polymers 0.000 claims description 8
- BJRNKVDFDLYUGJ-ZIQFBCGOSA-N alpha-Arbutin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-ZIQFBCGOSA-N 0.000 claims description 7
- 229940033280 alpha-arbutin Drugs 0.000 claims description 7
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 6
- 229920000570 polyether Polymers 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 5
- 229920002498 Beta-glucan Polymers 0.000 claims description 5
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 5
- 235000013532 brandy Nutrition 0.000 claims description 5
- 229920006037 cross link polymer Polymers 0.000 claims description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 2
- 241000235347 Schizosaccharomyces pombe Species 0.000 claims description 2
- 102100035140 Vitronectin Human genes 0.000 claims 1
- 108010031318 Vitronectin Proteins 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000009759 skin aging Effects 0.000 abstract description 3
- 241000628997 Flos Species 0.000 abstract 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 1
- 229960003966 nicotinamide Drugs 0.000 abstract 1
- 235000005152 nicotinamide Nutrition 0.000 abstract 1
- 239000011570 nicotinamide Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Cosmetics (AREA)
Abstract
一种玻色因及蓝铜肽双效组合精华液及其制备方法,该精华液包括A相、B相、C相及D相,A相主要组分有:酵母多糖类,双丙甘醇,烟酰胺;B相组分有:对羟基苯乙酮,1,2‑己二醇;C相主要组分有:二裂酵母发酵产物溶胞物、乙酸、乳酸、苯氧乙醇、苯甲酸钠,羟丙基四氢吡喃三醇;D相组分有:增溶剂,白兰花油。其制备方法,包括以下步骤:(1)D相搅拌溶解;(2)B相搅拌溶解;(3)A相加入乳化锅搅拌溶解;(4)开启降温;(5)B相加入至乳化锅中搅拌;(6)开启降温;(7)将C相加入乳化锅中搅拌,加入D相搅拌送检出料得到成品。本发明产品有效物更容易渗透到皮肤中去解决皮肤衰老问题并降低生产成本。
Description
技术领域
本发明涉及化妆品技术领域,尤其涉及一种玻色因及蓝铜肽双效组合精华液及其制备方法。
背景技术
市面上化妆品大多以传统的去离子水作为产品的溶剂载体,但是去离子水在制造过程中耗能大,还会产生很多的废水且去离子设备维修复杂,对水质的要求也高以致产品成本高,同时产品功效也不理想。
发明内容
针对现有技术的不足,本发明所解决的技术问题是取代产品生产过程中去离子水溶剂地位,降低产品制造成本同时增强产品功效。
为解决上述技术问题,本发明采用的技术方案是一种玻色因及蓝铜肽双效组合精华液,按质量份包括以下组分:
A相:
酵母多糖类60-80份,
β-葡聚糖0.1-1份,
双丙甘醇1-6份,
甘油聚醚-26 1-5份,
透明质酸钠0.01-0.5份,
EDTA二钠0.01-0.1份,
聚丙烯酸酯交联聚合物-6 0.1-1份,
烟酰胺1-5份,
α-熊果苷0.01-2份,
双-PEG-15甲基醚聚二甲基硅氧烷0.1-2份;
B相:
对羟基苯乙酮0.1-1份,
1,2-己二醇0.1-1份;
C相:
二裂酵母发酵产物溶胞物、乙酸、乳酸、苯氧乙醇、苯甲酸钠的混合物1-10份,
羟丙基四氢吡喃三醇0.1-5份,
蓝铜肽0.05-0.1份;
D相:
增溶剂0.2-2份,
白兰花油0.0015-0.5份。
进一步,C相中:
所述二裂酵母发酵产物溶胞物、乙酸、乳酸、苯氧乙醇、苯甲酸钠的混合物主要由以下组分质量百分比组成:二裂酵母发酵产物溶胞物98.5%、乙酸0.15%、乳酸0.1%、苯氧乙醇1%、苯甲酸钠0.25%。
本发明要解决的另一个技术问题是提供上述玻色因及蓝铜肽双效组合精华液的制备方法。
为此,本发明提供的技术方案是一种玻色因及蓝铜肽双效组合精华液的制备方法,包括以下步骤:
(1)将D相加入干净无水无菌器皿中加热至45℃搅拌溶解均匀后待用;
(2)将B相加入干净无水无菌器皿中加热至60℃搅拌完全溶解后待用;
(3)将A相加入乳化锅中加热至85-90℃搅拌并保温搅拌30分钟;
(4)保温完毕后开启降温,搅拌降温至60℃;
(5)降温至60℃后停止降温,将制备好的B相以60℃状态加入至乳化锅中,60℃保温搅拌10分钟;
(6)保温完毕后开启降温至45℃;
(7)降温至45℃后,将C相加入乳化锅中搅拌均匀,加入制备好的D相搅拌10分钟后送检合格后出料得到成品。
与现有技术相比,本发明采用发酵技术的滤液替代传统溶剂的去离子水,所制得的产品有效物更容易的渗透到皮肤中去,更好地解决了各种皮肤衰老问题并降低生产成本,且发酵滤液为可再生来源,亦不添加防腐剂,不会对环境造成污染。
具体实施方式
下面结合实施例对本发明的具体实施方式作进一步的说明,但不是对本发明的限定。
实施例1
一种玻色因及蓝铜肽双效组合精华液,按质量份包括以下组分:
A相:
酵母多糖类60份,
β-葡聚糖1份,
双丙甘醇1份,
甘油聚醚-26 5份,
透明质酸钠0.01份,
EDTA二钠0.1份,
聚丙烯酸酯交联聚合物-6 0.1份,
烟酰胺5份,
α-熊果苷0.01份,
双-PEG-15甲基醚聚二甲基硅氧烷2份;
B相:
对羟基苯乙酮0.1份,
1,2-己二醇1份;
C相:
二裂酵母发酵产物溶胞物、乙酸、乳酸、苯氧乙醇、苯甲酸钠的混合物1份,
羟丙基四氢吡喃三醇5份,
蓝同肽0.05份;
D相:
增溶剂2份,
白兰花油0.0015份。
进一步,C相中:
二裂酵母发酵产物溶胞物、乙酸、乳酸、苯氧乙醇、苯甲酸钠的混合物主要由以下组分质量百分比组成:二裂酵母发酵产物溶胞物98.5%、乙酸0.15%、乳酸0.1%、苯氧乙醇1%、苯甲酸钠0.25%。
实施例2
一种玻色因及蓝铜肽双效组合精华液,按质量份包括以下组分:
A相:
酵母多糖类70份,
β-葡聚糖0.5份,
双丙甘醇2份,
甘油聚醚-26 2份,
透明质酸钠0.2份,
EDTA二钠0.05份,
聚丙烯酸酯交联聚合物-6 0.5份,
烟酰胺3份,
α-熊果苷1份,
双-PEG-15甲基醚聚二甲基硅氧烷1份;
B相:
对羟基苯乙酮0.5份,
1,2-己二醇0.5份;
C相:
二裂酵母发酵产物溶胞物、乙酸、乳酸、苯氧乙醇、苯甲酸钠的混合物6份,
羟丙基四氢吡喃三醇3份,
蓝铜肽0.08份;
D相:
增溶剂1份,
白兰花油0.2份。
进一步,C相中:
二裂酵母发酵产物溶胞物、乙酸、乳酸、苯氧乙醇、苯甲酸钠的混合物主要由以下组分质量百分比组成:二裂酵母发酵产物溶胞物98.5%、乙酸0.15%、乳酸0.1%、苯氧乙醇1%、苯甲酸钠0.25%。
实施例3
一种玻色因及蓝铜肽双效组合精华液,按质量份包括以下组分:
A相:
酵母多糖类80份,
β-葡聚糖0.1份,
双丙甘醇6份,
甘油聚醚-26 1份,
透明质酸钠0.5份,
EDTA二钠0.01份,
聚丙烯酸酯交联聚合物-6 1份,
烟酰胺1份,
α-熊果苷2份,
双-PEG-15甲基醚聚二甲基硅氧烷0.1份;
B相:
对羟基苯乙酮1份,
1,2-己二醇0.1份;
C相:
二裂酵母发酵产物溶胞物、乙酸、乳酸、苯氧乙醇、苯甲酸钠的混合物1-10份,
羟丙基四氢吡喃三醇0.1份,
蓝铜肽0.1份;
D相:
增溶剂0.2份,
白兰花油0.5份。
进一步,C相中:
二裂酵母发酵产物溶胞物、乙酸、乳酸、苯氧乙醇、苯甲酸钠的混合物主要由以下组分质量百分比组成:二裂酵母发酵产物溶胞物98.5%、乙酸0.15%、乳酸0.1%、苯氧乙醇1%、苯甲酸钠0.25%。
上述实施例1至3制备方法,包括以下步骤:
(1)将D相加入干净无水无菌器皿中加热至45℃搅拌溶解均匀后待用;
(2)将B相加入干净无水无菌器皿中加热至60℃搅拌完全溶解后待用;
(3)将A相加入乳化锅中加热至85-90℃搅拌并保温搅拌30分钟;
(4)保温完毕后开启降温,搅拌降温至60℃;
(5)降温至60℃后停止降温,将制备好的B相以60℃状态加入至乳化锅中,60℃保温搅拌10分钟;
(6)保温完毕后开启降温至45℃;
(7)降温至45℃后,将C相加入乳化锅中搅拌均匀,加入制备好的D相搅拌10分钟后送检合格后出料得到成品。
为了更好的说明本发明的有益效果,进行以下功效评价实验:
抽取年龄阶段在21-40岁的志愿者60名,将本发明产品与市面上同类产品进行为期12周的“皱纹和细纹减少”,“皮肤弹性增加”、“密度和厚度减少”使用效果对比,结果如下:
产品组 | 非常有效 | 有效 | 较有效 | 没有效果 |
市售产品 | 3人 | 16人 | 11人 | 0 |
本发明产品 | 9人 | 14人 | 7人 | 0 |
从上表可知,本发明产品使用感觉非常有效的人数达9人明显优于现有市售产品的3人。
与现有技术相比,本发明采用发酵技术的滤液替代传统溶剂的去离子水,所制得的产品有效物更容易的渗透到皮肤中去,更好地解决了各种皮肤衰老问题并降低生产成本,且发酵滤液为可再生来源,亦不添加防腐剂,不会对环境造成污染。
以上结合实施例对本发明的实施方式做出了详细说明,但本发明不局限于所描述的实施方式。对于本领域技术人员而言,在不脱离本发明的原理和精神的情况下,对这些实施方式进行各种变化、修改、替换和变型仍落入本发明的保护范围内。
Claims (3)
1.一种玻色因及蓝铜肽双效组合精华液,其特征在于,按质量份包括以下组分:
A相:
酵母多糖类60-80份,
β-葡聚糖0.1-1份,
双丙甘醇1-6份,
甘油聚醚-26 1-5份,
透明质酸钠0.01-0.5份,
EDTA二钠0.01-0.1份,
聚丙烯酸酯交联聚合物-6 0.1-1份,
烟酰胺1-5份,
α-熊果苷0.01-2份,
双-PEG-15甲基醚聚二甲基硅氧烷0.1-2份;
B相:
对羟基苯乙酮0.1-1份,
1,2-己二醇0.1-1份;
C相:
二裂酵母发酵产物溶胞物、乙酸、乳酸、苯氧乙醇、苯甲酸钠的混合物1-10份,
羟丙基四氢吡喃三醇0.1-5份,
蓝铜肽0.05-0.1份;
D相:
增溶剂0.2-2份,
白兰花油0.0015-0.5份。
2.根据权利要求1所述的玻色因及蓝铜肽双效组合精华液,其特征在于,
C相中:所述二裂酵母发酵产物溶胞物、乙酸、乳酸、苯氧乙醇、苯甲酸钠的混合物主要由以下组分质量百分比组成:二裂酵母发酵产物溶胞物98.5%、乙酸0.15%、乳酸0.1%、苯氧乙醇1%、苯甲酸钠0.25%。
3.一种如权利要求1或2所述的玻色因及蓝铜肽双效组合精华液的制备方法,其特征在于,包括以下步骤:
(1)将D相加入干净无水无菌器皿中加热至45℃搅拌溶解均匀后待用;
(2)将B相加入干净无水无菌器皿中加热至60℃搅拌完全溶解后待用;
(3)将A相加入乳化锅中加热至85-90℃搅拌并保温搅拌30分钟;
(4)保温完毕后开启降温,搅拌降温至60℃;
(5)降温至60℃后停止降温,将制备好的B相以60℃状态加入至乳化锅中,60℃保温搅拌10分钟;
(6)保温完毕后开启降温至45℃;
(7)降温至45℃后,将C相加入乳化锅中搅拌均匀,加入制备好的D相搅拌10分钟后送检合格后出料得到成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010520199.6A CN111588657A (zh) | 2020-06-09 | 2020-06-09 | 一种玻色因及蓝铜肽双效组合精华液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010520199.6A CN111588657A (zh) | 2020-06-09 | 2020-06-09 | 一种玻色因及蓝铜肽双效组合精华液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111588657A true CN111588657A (zh) | 2020-08-28 |
Family
ID=72186374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010520199.6A Pending CN111588657A (zh) | 2020-06-09 | 2020-06-09 | 一种玻色因及蓝铜肽双效组合精华液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111588657A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113975220A (zh) * | 2021-10-29 | 2022-01-28 | 湖北省麦诗特生物科技有限公司 | 一种含羟丙基四氢吡喃三醇、发酵产物的抗衰老组合物及其应用 |
CN114397392A (zh) * | 2022-01-18 | 2022-04-26 | 宁波中盛产品检测有限公司 | 一种化妆品中玻色因有效物的离子色谱分析方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110063911A (zh) * | 2019-06-11 | 2019-07-30 | 包磊 | 一种复合小分子活性肽精华液 |
CN110522712A (zh) * | 2019-05-27 | 2019-12-03 | 广州好蝶化妆品有限公司 | 一种坏脸修护精华及制备方法 |
-
2020
- 2020-06-09 CN CN202010520199.6A patent/CN111588657A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110522712A (zh) * | 2019-05-27 | 2019-12-03 | 广州好蝶化妆品有限公司 | 一种坏脸修护精华及制备方法 |
CN110063911A (zh) * | 2019-06-11 | 2019-07-30 | 包磊 | 一种复合小分子活性肽精华液 |
Non-Patent Citations (2)
Title |
---|
天津美之路化妆品有限公司: "兰喜LANXI铜肽波色因精华液", 《电子凭证-国产非特殊用途化妆品备案信息服务平台,HTTP://FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/FW/PZ.JSP?PROCESSID=20200402151919S41CZ&NID=20200402151919S41CZ》 * |
广州市轩颜化妆品有限公司: "B-BLACK 玻色因蓝铜肽时光精华液", 《电子凭证-国产非特殊用途化妆品备案信息服务平台,HTTP://FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/FW/PZ.JSP?PROCESSID=202004081452149YU5V&NID=202004081452149YU5V》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113975220A (zh) * | 2021-10-29 | 2022-01-28 | 湖北省麦诗特生物科技有限公司 | 一种含羟丙基四氢吡喃三醇、发酵产物的抗衰老组合物及其应用 |
CN114397392A (zh) * | 2022-01-18 | 2022-04-26 | 宁波中盛产品检测有限公司 | 一种化妆品中玻色因有效物的离子色谱分析方法 |
CN114397392B (zh) * | 2022-01-18 | 2023-08-11 | 宁波中盛产品检测有限公司 | 一种化妆品中玻色因有效物的离子色谱分析方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111588657A (zh) | 一种玻色因及蓝铜肽双效组合精华液及其制备方法 | |
CN110915987A (zh) | 一种综合利用茶叶生产饲料的方法 | |
CN105147568A (zh) | 活性葡萄酒泥面膜及其制作方法 | |
CN110917055A (zh) | 一种寡肽修护精华液及其制作工艺 | |
CN110841490B (zh) | 一种复合膜及其制备方法和应用 | |
CN107412077A (zh) | 一种防晒修复肌肤的油橄榄叶紫外应激深层发酵提取物的制备方法 | |
CN113647394B (zh) | 一种防霉乳液及其制备方法 | |
CN107050217A (zh) | 一种芦荟凝胶的制备方法 | |
CN106722947A (zh) | 一种以枇杷皮为原料的复合酵素及其制备方法 | |
CN107057884A (zh) | 一种塑料培养皿清洗用洗涤剂及其制备方法 | |
CN110777116B (zh) | 肿瘤样本前处理方法 | |
CN108210441A (zh) | 一种用于美容保养的干细胞深层修复精华液 | |
CN113999737A (zh) | 一种植物酵素清洁剂及其制备方法 | |
CN107299077B (zh) | 一种牛脑垂体提取物的提取方法 | |
CN111568799A (zh) | 一种海参酵解素在美白产品中的应用 | |
CN105361165A (zh) | 一种有减肥效果的蛹虫草哈密瓜酵素制备方法 | |
CN114806972B (zh) | 一种利用天然低共熔溶剂制备高活性乳酸菌发酵剂的方法 | |
CN109315734A (zh) | 一种发酵型低亚硝酸盐含量的风味酸菜及其制备方法 | |
CN111616975B (zh) | 一种祛痘组合物及其制备方法 | |
CN114159358B (zh) | 一种有效清除自由基的修护面霜及其制备方法 | |
CN114941019B (zh) | 微生物发酵菌渣再利用的方法、裂褶菌菌渣的提取物及其应用 | |
CN112245358B (zh) | 一种佛手发酵提取液及其制备方法和其应用 | |
CN117645905A (zh) | 一种脱胶剂及其制备方法与使用方法 | |
CN106753782A (zh) | 一种利用气提除味生物柴油的方法 | |
CN116889536A (zh) | 马齿苋发酵液、含其皮肤外用剂、及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200828 |